Abstracts tagged "psoriatic arthritis and radiography"

Abstract Number: 671 • 2018 ACR/ARHP Annual Meeting
Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis
Carolina Ayelen Isnardi¹, Emilce E Schneeberger², Fernando Dal Pra³, E. Scheines^1,4, Andrea Lujan Coronel Ale⁵, Marina Natalia Fornaro⁶, Osvaldo Luis Cerda⁵ and Gustavo Citera⁵, ¹Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital Manuel Rocca, Buenos Aires, Argentina, ⁵Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ⁶Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina
Background/Purpose: There are many scores available to measure radiographic joint damage in patients with PsA, but most of them were developed for RA and then…
Abstract Number: 690 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Philip J. Mease¹, Désirée van der Heijde², Robert B.M. Landewé³, Shephard Mpofu⁴, Proton Rahman⁵, Hasan Tahir⁶, Atul Singhal⁷, Elke Böttcher⁸, Sandra V. Navarra⁹, Xuan Zhu¹⁰, Aimee Readie¹⁰, Luminita Pricop¹¹ and Ken Abrams¹⁰, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Leiden University Medical Centre, Leiden, Netherlands, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Memorial University of Newfoundland and Labrador, St. John's, NF, Canada, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Southwest Rheumatology, Dallas, TX, ⁸Rheumazentrum Favoriten, Vienna, Austria, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms and inhibited radiographic progression versus placebo (PBO) at Week (Wk) 24…
Abstract Number: 17L • 2017 ACR/ARHP Annual Meeting
Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study
Philip J Mease¹, Désirée van der Heijde², Robert B.M. Landewé³, Shephard Mpofu⁴, Proton Rahman⁵, Hasan Tahir⁶, Atul Singhal⁷, Elke Böttcher⁸, Sandra V. Navarra⁹, Karin Meiser⁴, Aimee Readie¹⁰, Luminita Pricop¹⁰ and Ken Abrams¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Medical Center, Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology, Memorial University of Newfoundland, St Johns, NF, Canada, ⁶Whipps Cross Hospital, London, United Kingdom, ⁷Southwest Rheumatology, Dallas, TX, ⁸Rheumazentrum Favoriten, Vienna, Austria, ⁹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has shown significant and rapid efficacy in psoriatic arthritis (PsA). We present primary results…
Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Pervin Sanci¹, Gokce Kenar², Berrin Zengin², Sadettin Uslu³, Aydan Koken³, Handan Yarkan³, Gerçek Can³, Merih Birlik³ and Fatos Onen², ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…
Abstract Number: 1592 • 2014 ACR/ARHP Annual Meeting
Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran², Richard J. Cook³ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis that leads to progressive joint damage. Biomarkers in addition to clinical features may help…
Abstract Number: 1549 • 2014 ACR/ARHP Annual Meeting
The Swedish Early Psoriatic Arhtritis (SWEPSA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities
Elke Theander¹, Tomas Husmark², Ulla Lindqvist³, Per T Larsson⁴, Annika Teleman⁵, Gerd-Marie Alenius⁶ and Mats Geijer⁷, ¹Skane University Hospital Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Rheumatology, Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Rheumatology, Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Rheumatology, Spenshult Rheumatological Hospital, Oskarström, Sweden, ⁶Rheumatology, Department of Public Health and Clinical Medicine, Rheumatology, Umeå University Hospital, Umeå, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden
Background/Purpose: The aim of this study is to describe early X-ray findings in psoriatic arthritis (PsA) patients from the SwePsA registry using the Wassenberg score,…
Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression
Deepak R. Jadon¹, Gavin Shaddick², William Tillett¹, Graham Robinson³, Charlotte Cavill¹, Nicola Waldron¹, Eleanor Korendowych¹ and Neil J McHugh⁴, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Royal United Hospital, Bath, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
Abstract Number: 74 • 2014 ACR/ARHP Annual Meeting
Influence of the Polymorphism IL1ß (-511 A/C) and IL6 (- 174 G/C) on the Activity, Radiographic Damage and Clinical Forms of Patients with Psoriatic Arthritis (PSA)
Tatiana Carranco¹, Noelia Cubino², Clara Cieza-Borrela³, Ismael Calero³, Maria Dolores Sanchez³, C. Hidalgo-Calleja⁴, Alba Quesada³, Andres Plata³, Agustin Diaz Alvarez³, Ricardo Usategui⁵, Rogelio Gonzalez⁵, C.a. Montilla-Morales⁴ and J. Del Pino-Montes⁴, ¹Reumathology, HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ²INTERNAL MEDICINE, HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ³HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ⁴University of Salamanca Hospital, Salamanca, Spain, ⁵IBSAL, SALAMANCA, Spain
Background/Purpose: PSA is a chronic inflammatory disease associated to psoriasis which affects the joints, vertebrae and enthesis. Interleukin-1 is an inflammatory cytokine. A higher expression…
Abstract Number: 566 • 2012 ACR/ARHP Annual Meeting
Effect of TNF Antagonists On Radiographic Progression in Psoriatic Arthritis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Radjiv Goulabchand¹, Gael Mouterde¹, Cédric Lukas², Thomas Barnetche³, Jacques Morel¹ and Bernard Combe¹, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France
Background/Purpose: Psoriatic arthritis (PsA) can cause important structural damages which can lead to disability. TNF antagonists have shown their clinical efficacy in PsA, but only…
Abstract Number: 541 • 2012 ACR/ARHP Annual Meeting
Prevalence of Sacroiliitis in the General Population: Comparative Analysis with Cutaneous Psoriasis and Psoriatic Arthritis
Jose Luis Fernandez-Sueiro¹, Carlos Fernandez-Lopez², S. Pertega-Diaz³, JA Pinto¹, E. Gonzalez², Francisco J. de Toro-Santos⁴ and Francisco J. Blanco V⁵, ¹Rheumatology Division, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ²Rheumatology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³Epidemiology and Statistics, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁴Reumatology Division, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁵Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: At least grade 2 unilateral sacroiliitis in the presence of spinal symptoms (defined as a combination of inflammatory back pain plus back stiffness) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].